EUVIMEDEUVIMED entdecken
Crossref

Long-Term Clinical and Hemodynamic Outcomes of Transcatheter Mitral Valve Replacement

Nicolas Groshenry, Gaspard Suc, Jules Mesnier, Clemence Delhomme, Audrey Cailliau, Eric Brochet, Gregory Ducrocq, Reza Farnoud, Linda Bleuze, Dominique Himbert, Skerdi Haviari, Bernard Iung und 1 weitere

JACC: Cardiovascular Interventions · 2026

DOI: 10.1016/j.jcin.2025.09.052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2026. Verfasst von Nicolas Groshenry und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Bichat Claude Bernard Hospital, Public, Paris, France; Université Paris City, Paris, France. Hauptthemen laut MEDLINE: Hemodynamics, Transcatheter Mitral Valve Replacement, Mitral Valve, Mitral Valve Insufficiency. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Long-term outcomes of transcatheter mitral valve replacement (TMVR) with balloon-expandable aortic prostheses remain uncertain. OBJECTIVES: The aim of this study was to evaluate long-term clinical and hemodynamic outcomes after TMVR. METHODS: All patients undergoing TMVR at the authors' center were included. Balloon-expandable transcatheter heart valves were implanted in all cases, usually using a trans-septal approach. The primary outcome was a composite of death or mitral reintervention (surgical or transcatheter replacement or transplantation). Secondary outcomes included mortality, hemodynamic changes, recurrent mitral regurgitation, structural valve deterioration (SVD), and TMVR failure. RESULTS: A total of 200 patients underwent TMVR: 60.5% (121 of 200) valve-in-valve, 22.5% (45 of 200) valve-in-ring, and 17% (34 of 200) valve-in-mitral annular calcification. The median age was 70 years (Q1-Q3: 52-80 years), and 67% were women (134 of 200). Median follow-up was 3.2 years (Q1-Q3: 1.2-6.8 years). Freedom from death or reintervention at 1, 5, and 8 years was 82% (95% CI: 77%-88%), 48% (95% CI: 40%-56%), and 20% (95% CI: 11%-29%), respectively, with worse outcomes in valve-in-ring and valve-in-mitral annular calcification compared with valve-in-valve (P < 0.01). Mean gradient increased slightly over time (+0.25 ± 0.07 mm Hg/y; P < 0.01), with a modest decrease in effective orifice area (-0.04 cm2/y; P < 0.01). Significant recurrent mitral regurgitation occurred in 5.5% of patients (11 of 200). Seven percent (14 of 200) developed severe SVD after 5.3 (Q1-Q3: 3.5-7.4 years), and 10% (20 of 200) developed TMVR failure after 4.4 (Q1-Q3: 1.8-6.7 years). CONCLUSIONS: TMVR with balloon-expandable aortic prostheses provides favorable long-term outcomes and acceptable durability, with low rates of severe SVD and valve failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemodynamicsTranscatheter Mitral Valve ReplacementMitral ValveMitral Valve InsufficiencyHeart Valve Prosthesis ImplantationHumansFemaleTime FactorsAgedHeart Valve ProsthesisAged, 80 and overProsthesis DesignRisk FactorsTreatment OutcomeMaleMiddle AgedRetrospective StudiesRecurrenceRecovery of FunctionProsthesis FailureBalloon Valvuloplasty

Stichwörter der Autor:innen

TMVRstructural valve deteriorationvalve durability

Autor:innen und Institutionen

  • Cardiology Department, Bichat Claude Bernard Hospital, Public, Paris, France; Université Paris City, Paris, France.
  • Cardiology Department, Bichat Claude Bernard Hospital, Public, Paris, France; Université Paris City, Paris, France; Inserm, UMR 1148, Paris, France.
  • Cardiology Department, Bichat Claude Bernard Hospital, Public, Paris, France.
  • Université Paris City, Paris, France; Epidemiology Biostatistics and Clinical Research Department, Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; Inserm UMR 1137, Paris, France.
  • Cardiology Department, Bichat Claude Bernard Hospital, Public, Paris, France; Université Paris City, Paris, France; Inserm, UMR 1148, Paris, France. Electronic address: marina.urena-alcazar@aphp.fr.

Zitieren

APA

Groshenry, N., Suc, G., Mesnier, J., Delhomme, C., Cailliau, A., Brochet, E., Ducrocq, G., Farnoud, R., Bleuze, L., Himbert, D., Haviari, S., Iung, B., & Urena, M. (2026). Long-Term Clinical and Hemodynamic Outcomes of Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.09.052

Vancouver

Groshenry N, Suc G, Mesnier J, Delhomme C, Cailliau A, Brochet E, et al. Long-Term Clinical and Hemodynamic Outcomes of Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Interventions. 2026. doi:10.1016/j.jcin.2025.09.052

BibTeX
@article{Groshenry2026,
  author = {Groshenry, Nicolas and Suc, Gaspard and Mesnier, Jules and Delhomme, Clemence and Cailliau, Audrey and Brochet, Eric and Ducrocq, Gregory and Farnoud, Reza and Bleuze, Linda and Himbert, Dominique and Haviari, Skerdi and Iung, Bernard and Urena, Marina},
  title = {Long-Term Clinical and Hemodynamic Outcomes of Transcatheter Mitral Valve Replacement},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1016/j.jcin.2025.09.052}
}
Kostenlos starten →